Abbott Laboratories
Research Abbott Laboratories (ABT) on Bullrun: valuation model: 2.0% overvalued, market cap USD 200.95B, P/E 37.5, dividend yield 2.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerABT
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Valuation signal2.0% overvalued
- Market capUSD 200.95B
- P/E37.5
- Dividend yield2.2%
- Financial periodQ1 2026
- RevenueUSD 11.16B
- Net incomeUSD 1.08B
- Free cash flowUSD 916.00M
- Gross margin56.2%
Valuation Snapshot
Bullrun's latest valuation model marks Abbott Laboratories as 2.0% overvalued; latest market cap is USD 200.95B; P/E is 37.5; dividend yield is 2.2%.
Peer valuation comparison
Latest P/E is 37.54x versus a Healthcare sector median of 24.46x (53.5% above).
Latest dividend yield is 2.21% versus a Healthcare sector median of 2.11% (4.7% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 44.33B | USD 6.52B | USD 7.40B | 56.4% | 3.72 | USD 8.52B | USD 12.93B | USD 52.13B |
| FY2024 | USD 41.95B | USD 13.40B | USD 6.35B | 55.4% | 7.64 | USD 7.62B | USD 14.13B | USD 47.66B |
| FY2023 | USD 40.11B | USD 5.72B | USD 5.06B | 55.2% | 3.26 | USD 6.90B | USD 14.68B | USD 38.60B |
| FY2022 | USD 43.65B | USD 6.93B | USD 7.80B | 56.1% | 3.91 | USD 9.88B | USD 16.77B | USD 36.69B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 200.95B | 37.5 | 2.1% | 2.48 |
| 2025 | 2025-12-31 | USD 217.58B | 33.7 | 1.9% | 2.36 |
| 2024 | 2024-12-31 | USD 195.87B | 14.8 | 1.9% | 2.2 |
| 2023 | 2023-12-29 | USD 191.09B | 37.4 | 1.9% | 2.04 |
| 2022 | 2022-12-30 | USD 191.43B | 24.8 | 1.7% | 1.88 |
| 2021 | 2021-12-31 | USD 248.28B | 35.7 | 1.3% | 1.8 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 2.48 USD, yield 2.2%.
| Year | Dividends/share |
|---|---|
| FY2025 | 2.4 USD |
| FY2024 | 2.24 USD |
| FY2023 | 2.08 USD |
| FY2022 | 1.92 USD |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Abbott Laboratories overvalued or undervalued?
Bullrun's valuation model currently marks Abbott Laboratories as 2.0% overvalued.
What is Abbott Laboratories's market cap?
Abbott Laboratories's market capitalization is USD 200.95B.
What is Abbott Laboratories's P/E ratio?
Abbott Laboratories's price-to-earnings (P/E) ratio is 37.5.
Does Abbott Laboratories pay a dividend?
Abbott Laboratories has a dividend yield of 2.2%.
What does Abbott Laboratories do?
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.